These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

189 related articles for article (PubMed ID: 35219602)

  • 1. The effect of osteoporosis treatment on bone mass.
    Appelman-Dijkstra NM; Oei HLDW; Vlug AG; Winter EM
    Best Pract Res Clin Endocrinol Metab; 2022 Mar; 36(2):101623. PubMed ID: 35219602
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Bone mineral density gains with a second 12-month course of romosozumab therapy following placebo or denosumab.
    Kendler DL; Bone HG; Massari F; Gielen E; Palacios S; Maddox J; Yan C; Yue S; Dinavahi RV; Libanati C; Grauer A
    Osteoporos Int; 2019 Dec; 30(12):2437-2448. PubMed ID: 31628490
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Drug therapy for osteoporosis in older adults.
    Reid IR; Billington EO
    Lancet; 2022 Mar; 399(10329):1080-1092. PubMed ID: 35279261
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Increased bone mineral density for 1 year of romosozumab, vs placebo, followed by 2 years of denosumab in the Japanese subgroup of the pivotal FRAME trial and extension.
    Miyauchi A; Dinavahi RV; Crittenden DB; Yang W; Maddox JC; Hamaya E; Nakamura Y; Libanati C; Grauer A; Shimauchi J
    Arch Osteoporos; 2019 Jun; 14(1):59. PubMed ID: 31168657
    [TBL] [Abstract][Full Text] [Related]  

  • 5. New therapeutic targets for osteoporosis.
    Anagnostis P; Gkekas NK; Potoupnis M; Kenanidis E; Tsiridis E; Goulis DG
    Maturitas; 2019 Feb; 120():1-6. PubMed ID: 30583758
    [TBL] [Abstract][Full Text] [Related]  

  • 6. FRAME Study: The Foundation Effect of Building Bone With 1 Year of Romosozumab Leads to Continued Lower Fracture Risk After Transition to Denosumab.
    Cosman F; Crittenden DB; Ferrari S; Khan A; Lane NE; Lippuner K; Matsumoto T; Milmont CE; Libanati C; Grauer A
    J Bone Miner Res; 2018 Jul; 33(7):1219-1226. PubMed ID: 29573473
    [TBL] [Abstract][Full Text] [Related]  

  • 7. One Year of Romosozumab Followed by Two Years of Denosumab Maintains Fracture Risk Reductions: Results of the FRAME Extension Study.
    Lewiecki EM; Dinavahi RV; Lazaretti-Castro M; Ebeling PR; Adachi JD; Miyauchi A; Gielen E; Milmont CE; Libanati C; Grauer A
    J Bone Miner Res; 2019 Mar; 34(3):419-428. PubMed ID: 30508316
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Treatment of postmenopausal osteoporosis with bone-forming and antiresorptive treatments: Combined and sequential approaches.
    Langdahl B
    Bone; 2020 Oct; 139():115516. PubMed ID: 32622871
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Current Status of Bone-Forming Therapies for the Management of Osteoporosis.
    Sølling ASK; Harsløf T; Langdahl B
    Drugs Aging; 2019 Jul; 36(7):625-638. PubMed ID: 31066015
    [TBL] [Abstract][Full Text] [Related]  

  • 10. A new antiresorptive approach to the treatment of fragility fractures: long-term efficacy and safety of denosumab.
    Tarantino U; Celi M; Feola M; Liuni FM; Resmini G; Iolascon G
    Aging Clin Exp Res; 2013 Oct; 25 Suppl 1():S65-9. PubMed ID: 24046047
    [TBL] [Abstract][Full Text] [Related]  

  • 11. [[Antiresorptive agents in the treatment of osteoporosis].
    Novak S
    Reumatizam; 2014; 61(2):89-94. PubMed ID: 25427401
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Denosumab versus romosozumab for postmenopausal osteoporosis treatment.
    Kobayakawa T; Miyazaki A; Saito M; Suzuki T; Takahashi J; Nakamura Y
    Sci Rep; 2021 Jun; 11(1):11801. PubMed ID: 34083636
    [TBL] [Abstract][Full Text] [Related]  

  • 13. [Osteoporosis].
    Uebelhart B; Ferrari S
    Rev Med Suisse; 2017 Jan; 13(544-545):88-90. PubMed ID: 28703545
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Romosozumab: A Review in Postmenopausal Osteoporosis.
    Paik J; Scott LJ
    Drugs Aging; 2020 Nov; 37(11):845-855. PubMed ID: 32909197
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Elevated Bone Hardness Under Denosumab Treatment, With Persisting Lower Osteocyte Viability During Discontinuation.
    Jähn-Rickert K; Wölfel EM; Jobke B; Riedel C; Hellmich M; Werner M; McDonald MM; Busse B
    Front Endocrinol (Lausanne); 2020; 11():250. PubMed ID: 32499755
    [TBL] [Abstract][Full Text] [Related]  

  • 16. When and how to stop denosumab therapy in a patient with osteoporosis.
    Goulden EL; Crowley RK
    Clin Endocrinol (Oxf); 2023 May; 98(5):649-653. PubMed ID: 35470448
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Bone Mineral Density Loss and Fracture Risk After Discontinuation of Anti-osteoporotic Drug Treatment: A Narrative Review.
    Elbers LPB; Raterman HG; Lems WF
    Drugs; 2021 Sep; 81(14):1645-1655. PubMed ID: 34524681
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Rebound-associated vertebral fractures after discontinuation of denosumab-from clinic and biomechanics.
    Popp AW; Zysset PK; Lippuner K
    Osteoporos Int; 2016 May; 27(5):1917-21. PubMed ID: 26694598
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Denosumab: A Review in Postmenopausal Osteoporosis.
    Deeks ED
    Drugs Aging; 2018 Feb; 35(2):163-173. PubMed ID: 29435849
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Monoclonal antibodies for treatment of osteoporosis.
    Kroupova K; Palicka V; Rosa J
    Drugs Today (Barc); 2023 Mar; 59(3):195-204. PubMed ID: 36847627
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.